CS
KYNB

Candriam SCA’s Kyntra Bio KYNB Stock Holding History

Candriam SCA’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-11,539
Closed -$2.95M – 822
2021
Q3 		$2.95M Hold
11,539
– – 0.02% 498
2021
Q2 		$7.68M Buy
11,539
+4,154
+56% +$2.39M 0.05% 327
2021
Q1 		$6.58M Hold
7,385
– – 0.05% 329
2020
Q4 		$6.85M Sell
7,385
-2,737
-27% -$2.88M 0.05% 337
2020
Q3 		$10.4M Buy
10,122
+1,566
+18% +$1.69M 0.1% 223
2020
Q2 		$8.67M Sell
8,556
-700
-8% -$650K 0.09% 240
2020
Q1 		$9.7M Hold
9,256
– – 0.11% 216
2019
Q4 		$9.93M Sell
9,256
-10,260
-53% -$10.5M 0.11% 218
2019
Q3 		$18M Buy
19,516
+17,476
+857% +$19.2M 0.24% 89
2019
Q2 		$2.29M Sell
2,040
-9,596
-82% -$10.5M 0.03% 485
2019
Q1 		$15.8M Sell
11,636
-2,400
-17% -$3.25M 0.2% 114
2018
Q4 		$16.2M Sell
14,036
-2,400
-15% -$2.7M 0.25% 90
2018
Q3 		$25M Buy
16,436
+8,912
+118% +$13.7M 0.33% 62
2018
Q2 		$11.8M Buy
7,524
+1,384
+23% +$1.8M 0.19% 141
2018
Q1 		$7.09M Sell
6,140
-400
-6% -$527K 0.12% 213
2017
Q4 		$7.75M Sell
6,540
-3,400
-34% -$4.26M 0.13% 193
2017
Q3 		$13.4M Sell
9,940
-4,500
-31% -$4.74M 0.23% 111
2017
Q2 		$11.7M Sell
14,440
-1,320
-8% -$919K 0.22% 124
2017
Q1 		$9.71M Sell
15,760
-2,640
-14% -$1.61M 0.19% 148
2016
Q4 		$9.84M Sell
18,400
-840
-4% -$419K 0.23% 122
2016
Q3 		$9.96M Buy
19,240
+8,400
+77% +$3.96M 0.24% 110
2016
Q2 		$4.45M Sell
10,840
-720
-6% -$330K 0.12% 201
2016
Q1 		$6.12M Buy
11,560
+1,160
+11% +$578K 0.15% 156
2015
Q4 		$7.92M Buy
10,400
+2,372
+30% +$1.57M 0.21% 123
2015
Q3 		$4.4M Buy
+8,028
New +$4.86M 0.11% 226

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Candriam SCA's KYNB Position: Q4 2021 in Review

Candriam SCA sold out of Kyntra Bio (KYNB) in Q4 2021, closing a stake of 11,539 shares — an estimated $2.95M sold.

Candriam SCA first reported a position in KYNB in Q3 2015 and held it in 25 quarters. The position peaked at $25M in Q3 2018. 162 funds tracked by Wall St. Rank hold KYNB as of Q4 2021.

  • Candriam SCA reported no remaining Kyntra Bio position as of Q4 2021 after selling out during the quarter.
  • Candriam SCA sold 11,539 Kyntra Bio shares in Q4 2021, an estimated $2.95M.
  • Candriam SCA first reported a position in Kyntra Bio in Q3 2015 and held it in 25 quarters.
  • Candriam SCA's Kyntra Bio position peaked at $25M in Q3 2018.
  • 162 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2021.

Based on Candriam SCA's 13F filing for Q4 2021, filed 10 Feb 2022.